TScan Therapeutics Presents Promising Updated Phase 1 Clinical Results on TSC-100 and TSC-101 at the 2024 Tandem Meetings of ASTCT and CIBMTR
“We are excited to report updated data from our heme program, with eight patients across our treatment arms and six patients in our control arm.
- “We are excited to report updated data from our heme program, with eight patients across our treatment arms and six patients in our control arm.
- We remain encouraged to see that no relapses have occurred to date in treated patients, four of whom have been on the study for over ten months.
- Unfortunately, roughly 40% of patients relapse following HCT, at which point there are limited treatment options and a poor prognosis.
- A replay will be made available on the “ Events and Presentations ” section of the Company’s investor relations website at ir.tscan.com .